	US 12,433,949 B2
	Sustained release delivery systems comprising traceless linkers
Christopher M. Adams, Arlington, MA (US); Myriam April, Cambridge, MA (US); Tanzina Fazal, Burlington, MA (US); Cornelia Jutta Forster, Pelham, NH (US); Edward Charles Hall, Boston, MA (US); and Cameron Chuck-munn Lee, Cambridge, MA (US)
Assigned to Novartis AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Nov. 11, 2022, as Appl. No. 18/054,767.
Application 18/054,767 is a division of application No. 16/901,601, filed on Jun. 15, 2020, abandoned.
Application 16/901,601 is a division of application No. 15/957,474, filed on Apr. 19, 2018, granted, now 10,751,417, issued on Aug. 25, 2020.
Claims priority of provisional application 62/487,888, filed on Apr. 20, 2017.
Prior Publication US 2023/0201353 A1, Jun. 29, 2023
Int. Cl. A61K 47/36 (2006.01); A61K 9/00 (2006.01); A61K 31/496 (2006.01); A61K 47/10 (2017.01); A61K 47/22 (2006.01); A61K 47/61 (2017.01); A61K 47/69 (2017.01); A61P 27/02 (2006.01)

CPC A61K 47/36 (2013.01) [A61K 9/0048 (2013.01); A61K 31/496 (2013.01); A61K 47/10 (2013.01); A61K 47/22 (2013.01); A61K 47/61 (2017.08); A61K 47/6903 (2017.08); A61P 27/02 (2018.01)]

7 Claims

1. A drug delivery system or pharmaceutically acceptable salt thereof characterized in that is represented by Formula (XXX), where Drug is a biologically active moiety comprising at least one primary or secondary amine or a ring nitrogen atom of an azaheteroaryl ring; w is the number of repeating PEG monomer units having a nominal average molecular weight of 2 kDa; q is independently at each occurrence 1, 2, or 3; m is 1 or 0; p is a weighted average length of between 2 and 50; and R⁴is methyl, ethyl, propyl, isopropyl, 1-methyl-cyclopropyl, or methoxymethyl: